Dopamine is a chemically simple molecule with an outsized role in the nervous system. It acts as a neurotransmitter, carrying signals between nerve cells and helping regulate movement, motivation, reward, attention and several other physiological processes. Abnormal dopamine signaling is associated with neurological and psychiatric conditions including Parkinson’s disease, Alzheimer’s disease and schizophrenia. Yet measuring dopamine outside a laboratory is difficult. The molecule is present in complex mixtures alongside compounds such as ascorbic acid and uric acid, which can generate similar electrical responses at an electrode. Dopamine concentrations can also change rapidly and vary substantially between biological compartments, meaning that a useful sensor must be sensitive, selective, fast and capable of working with very small sample volumes.

The new device uses electrochemistry to solve part of that problem. Rather than identifying dopamine through a bulky analytical instrument, the sensor measures the current produced when dopamine undergoes oxidation at the electrode surface. The resulting electrical signal depends on the amount of dopamine available to react. In practice, however, an unmodified electrode may provide a weak or poorly resolved response. The researchers therefore coated a screen-printed electrode with a composite engineered to improve several stages of the sensing process at once. The resulting MX-CD-Au/SPE sensor uses MXene as a conductive framework, banana-peel carbon dots as functional nanoscale components and gold nanoparticles to increase catalytic activity and facilitate electron transfer.

MXenes are two-dimensional transition-metal carbides or nitrides known for their electrical conductivity, hydrophilic surfaces and large effective area. Their sheet-like structure can provide abundant sites where target molecules interact and where electrochemical reactions occur. In the composite, MXene acts as a conductive highway, allowing electrons generated during dopamine oxidation to move efficiently toward the electrode. Its surface chemistry can also support the attachment and distribution of other nanomaterials. The researchers paired it with gold nanoparticles, which are widely used in electrochemical sensing because their high surface area and favorable electronic properties can accelerate redox reactions. Together, the materials were intended to amplify the signal without requiring a large electrode or a conventional laboratory setup.

The third component, carbon dots produced from banana peel, adds a sustainability angle as well as chemical functionality. Carbon dots are nanoscale carbon particles with abundant surface groups that can influence how molecules bind and how electrons are transferred. In this design, the bio-derived dots were distributed with MXene and gold, creating a hybrid surface rather than three isolated materials operating independently. Structural and morphological characterization confirmed that the components had been integrated uniformly, according to the researchers. That architecture is important because a composite’s performance depends not only on the properties of its ingredients but also on how closely those ingredients contact one another. Efficient interfaces can reduce resistance to electron movement and expose more active sites to the sample.

The sensor produced a linear response to dopamine from 2 to 914 micromolar and reported a detection limit of 0.15 micromolar. A linear range means that, within those limits, changes in dopamine concentration correspond predictably to changes in the measured electrochemical signal, allowing an unknown sample to be quantified against a calibration curve. The low detection limit indicates that the device could register relatively small amounts of dopamine under the reported experimental conditions. The researchers also tested selectivity in the presence of common interferents, a critical challenge for real biological samples. According to the study, the MX-CD-Au/SPE platform retained a strong dopamine response despite those competing substances, suggesting that the engineered surface improved discrimination as well as sensitivity.

To test whether the chemistry worked beyond prepared solutions, the team examined several increasingly realistic biological settings. First, they added known amounts of dopamine to rat brain homogenate, a complex mixture containing proteins, salts, metabolites and cellular debris. The sensor quantified the spiked neurotransmitter in that matrix, demonstrating that the response was not limited to a clean laboratory solution. The researchers then monitored dopamine released from human SH-SY5Y neuroblastoma cells after stimulation with potassium ions. Raising extracellular potassium concentration depolarizes cell membranes, encouraging electrically excitable cells to release signaling molecules. Detecting the resulting extracellular dopamine provided an in vitro test of whether the sensor could follow a biologically generated signal rather than merely measure a prepared standard.

The platform’s most attention-grabbing feature is its one-drop format. Instead of requiring milliliters of sample, the system is designed to analyze a microvolume droplet placed directly on the sensing area. The researchers integrated the electrode with a smartphone-compatible portable device and used it to quantify dopamine in droplets of human sweat. Sweat is attractive for non-invasive monitoring because it can be collected without needles, although it is chemically variable and generally does not provide a direct readout of neurotransmitter levels in the brain. A sweat measurement therefore should not be interpreted as a simple substitute for neural sampling. It is better understood as a demonstration that the sensor can operate in a readily accessible biological fluid while using only a very small amount of material. The study reports that sample collection followed the Declaration of Helsinki, received institutional review approval and involved informed consent.

The work illustrates how several trends in biosensing are converging: nanostructured electrodes, waste-derived materials, smartphone integration and microvolume analysis. Screen-printed electrodes are especially useful for portable devices because they can be manufactured inexpensively and in compact formats, while smartphones can provide display, processing and connectivity without adding a dedicated laboratory instrument. A one-drop system could eventually support rapid measurements in settings where centralized testing is impractical. However, substantial barriers remain before such a platform could be used to diagnose or manage disease. Future studies would need to establish long-term stability, calibration across individuals, resistance to sweat composition differences, manufacturing reproducibility, storage life, clinical accuracy and the relationship between peripheral dopamine measurements and neurological status. The current findings show that the composite can detect dopamine in several experimental matrices; they do not yet demonstrate clinical diagnosis, continuous wearable operation or direct measurement of dopamine inside the human brain. Funded by the National Research Foundation of Korea, the study nevertheless presents a striking example of how a discarded fruit peel and advanced nanomaterials could be combined into a pocket-sized tool for real-time chemical sensing.

The blood-brain barrier has long been a double-edged sword in neuroscience and drug delivery. While it protects the brain from potentially harmful substances, it simultaneously restricts most therapeutics from crossing into the brain parenchyma, particularly large molecules and advanced nanostructures. The innovation detailed in this study involves circumventing the BBB entirely by utilizing the intranasal route, allowing direct access to the central nervous system through the olfactory and trigeminal nerves. This method significantly reduces systemic exposure and leverages the natural anatomical pathways to facilitate rapid brain delivery.

Central to this breakthrough is the design of a nanolamellar structure engineered to sequentially release payloads directly into mitochondria—the powerhouses of the cell and pivotal players in ischemic stroke pathology. Mitochondrial dysfunction is a hallmark of ischemic injury, leading to energy failure and cell death. Targeting mitochondria presents a highly strategic therapeutic avenue, as the restoration of mitochondrial function can halt or reverse the cascade of neuronal damage initiated by stroke.

The nanolamellar system is bioengineered with exquisite precision, incorporating components that navigate the biological milieu of the brain’s extracellular matrix while preserving stability during passage from the nasal epithelium. This system is layered at the nanoscale, with each layer programmed to release therapeutic agents sequentially, facilitating a timed release that mirrors the pathophysiological progression of ischemic injury. This ensures drugs are delivered at the optimal timeframes for maximum neuroprotection and tissue repair.

Intranasal administration, the route chosen for this delivery system, circumvents enzymatic degradation and hepatic first-pass metabolism, common pitfalls in systemic drug delivery. It enables high bioavailability of therapeutic agents directly to the brain. The olfactory nerve pathways provide a direct conduit for nanolamellar particles to reach various brain regions, including the ischemic penumbra— the zone critical for neuroprotection and the potential rescue of neurons.

Technically, the nanolamellar system is fabricated through advanced bioengineering techniques combining lipid-based nanotechnology with mitochondrial targeting ligands. The researchers employed a modular design that integrates hydrophobic and hydrophilic regions, facilitating the encapsulation of diverse therapeutic molecules ranging from antioxidant enzymes to small molecular drugs. The surface of these lamellar structures is functionalized with mitochondria-penetrating peptides, improving mitochondrial membrane permeabilization and subsequent drug delivery within the targeted organelles.

Upon reaching the mitochondria, the controlled release mechanism triggers the sequential liberation of agents aimed at reducing oxidative stress, restoring bioenergetics, and preventing apoptotic signaling cascades. This multi-pronged approach is critical for halting the extensive neuronal death cascade that follows ischemic stroke events. Initial preclinical models demonstrated remarkable reduction in infarct size, improved neurological function, and marked preservation of neuronal morphology compared to conventional treatments.

The implications of this study extend beyond ischemic stroke. The intranasal nanolamellar carrier system presents a versatile platform that could be adapted for a broad spectrum of neurological disorders characterized by mitochondrial dysfunction, including neurodegenerative diseases like Alzheimer’s and Parkinson’s disease. This versatility positions the nanolamellar system as a paradigm shift in central nervous system drug delivery, marrying precision targeting with non-invasive administration.

Crucially, the safety profile of the nanolamellar system was thoroughly evaluated in animal models, revealing excellent biocompatibility and negligible inflammatory response within the nasal mucosa and brain tissues. These findings are vital, given that chronic inflammation can exacerbate neurodegenerative processes and undermine therapeutic efficacy. The bioengineered components are biodegradable, ensuring clearance without accumulation, a common issue with some nanoparticle-based therapies.

The sequential release strategy employed in this nanolamellar system takes inspiration from the complex temporal dynamics of ischemic brain injury. Unlike traditional single-dose therapies, this system administers therapeutics in stages, aligned with distinct phases of ischemic pathology—initial oxidative stress, mitochondrial depolarization, and later apoptotic signaling. This temporal precision offers a sophisticated therapeutic intervention, setting a new benchmark for neuroprotective treatments.

Another exciting facet of this research is the potential for personalized medicine applications. By modifying the nanolamellar layers or the targeting peptides, the system’s payload and release kinetics can be fine-tuned to individual patient profiles, stroke severity, or comorbid conditions. Such customization could revolutionize how stroke therapies are administered, moving away from a one-size-fits-all paradigm toward highly individualized regimens.

The scalability and manufacturability of the nanolamellar system also catch attention. The researchers outlined a reproducible production process amenable to large-scale manufacturing under Good Manufacturing Practice (GMP) standards. This aspect is crucial for translating laboratory success into clinical reality, overcoming common bottlenecks faced by nanomedicine technologies in commercial deployment.

In the broader context of stroke management, timely intervention remains the most critical determinant of patient outcomes. The intranasal nanolamellar delivery system’s rapid brain targeting can potentially extend the therapeutic window, a holy grail in stroke treatment. Early preclinical evidence suggests the system remains effective even when administered hours after ischemic onset, offering hope for patients who present late to medical facilities.

Moreover, this bioengineered system may synergize with current reperfusion therapies, such as thrombolysis or mechanical thrombectomy, by mitigating reperfusion injury—a significant source of additional neural damage following the restoration of blood flow. The ability to support mitochondrial health during this critical phase could enhance recovery and attenuate secondary injury mechanisms.

Looking forward, the translation to human clinical trials will necessitate addressing several challenges, including refining dosing strategies, optimizing delivery devices for consistent intranasal administration, and validating long-term safety and efficacy. Nonetheless, the foundation laid by Yin and colleagues creates a promising pipeline for next-generation stroke therapeutics, marrying cutting-edge bioengineering with translational neuroscience.

This pioneering research underscores the transformative potential of integrating nanotechnology, mitochondrial biology, and innovative delivery routes to tackle previously insurmountable neurological challenges. With ischemic stroke being a leading cause of death and disability worldwide, the global impact of such advances cannot be overstated. This study heralds a new era of targeted neurotherapeutics characterized by precision, efficacy, and patient-centric design.

As the neuroscience community eagerly anticipates further developments, this work serves as a powerful reminder of the critical importance of interdisciplinary approaches in medical innovation. The fusion of molecular engineering, pharmacology, and neuroanatomy demonstrated here exemplifies how fundamental scientific insights translate into therapeutic breakthroughs with the capacity to save millions of lives.

Subject of Research:
Intranasal delivery system to bypass the blood-brain barrier for targeted mitochondrial therapy in ischemic stroke.

Article Title:
Intranasal blood-brain barrier bypass enables sequential mitochondria-targeted bioengineered nanolamellar system for ischemic stroke therapy.

Article References:
Yin, Y., Li, Z., Shu, W. et al. Intranasal blood-brain barrier bypass enables sequential mitochondria-targeted bioengineered nanolamellar system for ischemic stroke therapy. Nat Commun (2026). https://doi.org/10.1038/s41467-025-68024-5

Image Credits:
AI Generated

At its core, the challenge in TBI treatment lies not only in the immediacy of the initial trauma but in the secondary waves of inflammation, oxidative stress, and neurodegeneration that continue unchecked long after the event. Traditional clinical approaches often fall short—they are hampered by poor penetration of therapeutic agents through the blood-brain barrier and limited capacity for real-time monitoring of tissue responses. Theranostic nanomaterials cut through these constraints by fusing diagnostic and therapeutic functionalities into a single, dynamic platform. These nanomaterials are designed to transverse the brain’s natural defense systems and deliver precise payloads of neuroprotective or anti-inflammatory drugs directly to damaged sites, while concurrently acting as nanosensors that capture vital biofeedback.

What sets these nanoparticles apart is their remarkable ability to respond to the biochemical milieu unique to injured neural tissue. For instance, they can sense changes in pH, elevated oxidative stress markers, or the activation of specific enzymes—all hallmarks of the secondary damage process in TBI. Through these biological cues, the nanoparticles can modulate their drug release profiles or enhance imaging signals, enabling clinicians to visualize therapeutic impact and adjust treatment strategies in real time. This dual capability embodies the “theranostic” principle, merging therapy and diagnostics into one streamlined nanoscale intervention.

The review conducted by Professor Kim’s team delves into a rich spectrum of nanotherapeutic platforms that have shown promise in preclinical models of TBI. Among these, PEGylated-polystyrene nanoparticles feature surface modifications that prolong circulation time and improve brain targeting. Porous silicon nanoparticles offer large surface areas for drug loading and controlled biodegradation. Carbon dot nanoparticles, with their inherent fluorescence and antioxidant properties, serve both as imaging agents and protectants against reactive oxygen species. Dendrimer nanoparticles provide highly branched architectures facilitating multi-drug conjugation. Notably, lipid nanoparticles (LNPs) have demonstrated exceptional efficiency in delivering neuroprotective molecules to injured brain regions, exploiting their biocompatibility and ability to merge seamlessly with cellular membranes.

Beyond drug delivery, carbon-dot nanozymes emerge as a marvel of bioinspired engineering, mimicking natural enzymatic activity to neutralize harmful reactive molecules pervasive in post-TBI oxidative environments. These nanozymes reduce oxidative stress by catalyzing the breakdown of free radicals, thus addressing one of the key pathological drivers of secondary brain injury—a process previously difficult to target therapeutically.

The diagnostic arm of theranostic nanomaterials also comprises an array of sophisticated nanosensors tailored to the complex extracellular matrix and biomarker milieu of the damaged brain. Peptide-based sensors can selectively bind to enzymes or proteins upregulated in TBI, whereas extracellular matrix (ECM)-targeted and fibrinogen-based sensors detect structural and clotting abnormalities, respectively. These nanosensor platforms provide clinicians with a real-time portrait of injury evolution, enabling dynamic assessment of severity and response to interventions.

Fresh horizons are being opened by integrating these nanoscale technologies with cutting-edge artificial intelligence and bioengineering techniques. Machine learning algorithms can decipher the intricate data patterns produced by nanosensors, facilitating predictive modeling of injury trajectories and personalized therapeutic regimens. Bioengineered nanoplatforms that adapt in response to evolving biochemical signals promise a future where treatments are not only targeted and minimally invasive but continuously optimized through intelligent feedback loops.

Nonetheless, translating these laboratory achievements into safe, effective clinical treatments requires surmounting critical challenges. Foremost among these is ensuring the biocompatibility and safety of nanoparticles over extended periods. To address concerns over chronic accumulation and potential toxicity, Professor Kim highlights the importance of rationally designing nanomaterials that can degrade in response to endogenous stimuli—such as changes in pH or specific enzymatic activities present in the injured brain environment—thus minimizing residual deposits and adverse effects over time.

The implications of these advances for neurotrauma care are profound. By melding diagnosis and therapy within a single nanoplatform, theranostic nanomaterials promise to accelerate injury detection, sharpen drug delivery precision, and enable real-time monitoring of recovery. This integrated approach heralds a shift toward personalized brain medicine, where patient outcomes are enhanced through continuous, data-driven intervention tailored to individual pathophysiology.

In conclusion, the pioneering work from Pusan National University crystallizes the potential of theranostic nanomaterials to dramatically improve the prognosis for TBI patients. By harnessing nanoscale engineering, molecular sensing, and intelligent analytics, these innovations could unlock new therapeutic avenues, reducing the burden of brain injuries and restoring hope to millions affected worldwide.

Subject of Research: Not applicable

Article Title: Recent advances in theranostic nanomaterials for overcoming traumatic brain injury

News Publication Date: 29-Oct-2025

References: DOI: 10.1186/s12951-025-03685-4

Image Credits: Prof. Yun Hak Kim from Pusan National University, Republic of Korea